Bead-Based Immunoassay Developed to Measure Vimentin Autoantibodies
By LabMedica International staff writers Posted on 01 Jul 2014 |
An immunobead assay has been developed to quantitate circulating levels of vimentin antibodies, and, to test the feasibility of these autoantibodies as a biomarker for clinical diagnosis.
Vimentin is an intermediate filament protein generally expressed in the cytosol of many adult cell types, including leukocytes, fibroblasts and endothelial cells. Several tissue and/or injury-specific isoforms of vimentin are known to exist that may trigger autoimmune responses due to aberrant structural or conformational variations.
Scientists at the Rush University Medical Center (Chicago, IL, USA) evaluated the efficacy of the newly developed assay on discarded serum samples collected from 51 renal transplant patients with allograft dysfunction and compared the results with control specimens from 20 age and gender matched control individuals.
Magplex Microspheres (Luminex Corporation; Austin, TX, USA) were used in the development of this vimentin autoantibody assay and were processed in batches of 106 beads. Recombinant human vimentin (R&D Systems, Minneapolis, MN, USA) were added to the MagPlex beads and serum samples were processed. Assay performance and microsphere validation was accomplished by reading on a Luminex FlexMap 3-D system with a minimum of 50 bead reads per well. Median fluorescence intensity (MFI) values were reported for the conditions to permit the evaluation of coupling efficiency and preliminary evaluation of an assay range.
Preliminary evaluation of the assay demonstrates significantly higher circulating levels of anti-vimentin antibodies in 51 cases of renal allograft rejection relative to 20 cases of age-matched controls. From repeated testing of three distinct batches of assays provide assay range parameters of 0.18–15 μg/mL, median inter-assay recovery parameter was within 1% of completion, and interassay variation was at 7%.
The authors concluded that their direct capture assay for vimentin autoantibodies was successfully developed and analytically validated. Preliminary evaluation of this assay against patient materials was promising and justifies additional testing with larger cohorts in future studies. The study was published in the May 2014 issue of Journal of Immunological Methods.
Related Links:
Rush University Medical Center
Luminex Corporation
R&D Systems
Vimentin is an intermediate filament protein generally expressed in the cytosol of many adult cell types, including leukocytes, fibroblasts and endothelial cells. Several tissue and/or injury-specific isoforms of vimentin are known to exist that may trigger autoimmune responses due to aberrant structural or conformational variations.
Scientists at the Rush University Medical Center (Chicago, IL, USA) evaluated the efficacy of the newly developed assay on discarded serum samples collected from 51 renal transplant patients with allograft dysfunction and compared the results with control specimens from 20 age and gender matched control individuals.
Magplex Microspheres (Luminex Corporation; Austin, TX, USA) were used in the development of this vimentin autoantibody assay and were processed in batches of 106 beads. Recombinant human vimentin (R&D Systems, Minneapolis, MN, USA) were added to the MagPlex beads and serum samples were processed. Assay performance and microsphere validation was accomplished by reading on a Luminex FlexMap 3-D system with a minimum of 50 bead reads per well. Median fluorescence intensity (MFI) values were reported for the conditions to permit the evaluation of coupling efficiency and preliminary evaluation of an assay range.
Preliminary evaluation of the assay demonstrates significantly higher circulating levels of anti-vimentin antibodies in 51 cases of renal allograft rejection relative to 20 cases of age-matched controls. From repeated testing of three distinct batches of assays provide assay range parameters of 0.18–15 μg/mL, median inter-assay recovery parameter was within 1% of completion, and interassay variation was at 7%.
The authors concluded that their direct capture assay for vimentin autoantibodies was successfully developed and analytically validated. Preliminary evaluation of this assay against patient materials was promising and justifies additional testing with larger cohorts in future studies. The study was published in the May 2014 issue of Journal of Immunological Methods.
Related Links:
Rush University Medical Center
Luminex Corporation
R&D Systems
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Immunology News
- AI Predicts Tumor-Killing Cells with High Accuracy
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form